KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaboration Revenue BreakdownCollaboration Revenue Breakdown AnnualContractual ObligatonsCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Provision For Income TaxNon Gaap ExpensesNon Gaap Expenses AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue Breakdown AnnualProperty And Equipment, Net BreakdownRevenue By ProductRevenue By Product %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Pmo Product Revenues, Net BreakdownTotal Pmo Product Revenues, Net Breakdown Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Gross Profit (2016 - 2025)

Historic Gross Profit for Sarepta Therapeutics (SRPT) over the last 9 years, with Q2 2025 value amounting to $458.5 million.

  • Sarepta Therapeutics' Gross Profit rose 4401.8% to $458.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.7 billion, marking a year-over-year increase of 2632.83%. This contributed to the annual value of $1.6 billion for FY2024, which is 4482.07% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Gross Profit stood at $458.5 million, which was up 4401.8% from $526.1 million recorded in Q4 2024.
  • Sarepta Therapeutics' Gross Profit's 5-year high stood at $526.1 million during Q4 2024, with a 5-year trough of $124.6 million in Q1 2021.
  • For the 5-year period, Sarepta Therapeutics' Gross Profit averaged around $266.6 million, with its median value being $227.1 million (2023).
  • As far as peak fluctuations go, Sarepta Therapeutics' Gross Profit skyrocketed by 1467.5% in 2022, and later soared by 6610.22% in 2024.
  • Sarepta Therapeutics' Gross Profit (Quarter) stood at $169.7 million in 2021, then skyrocketed by 34.12% to $227.6 million in 2022, then soared by 54.9% to $352.6 million in 2023, then soared by 49.21% to $526.1 million in 2024, then decreased by 12.84% to $458.5 million in 2025.
  • Its Gross Profit was $458.5 million in Q2 2025, compared to $526.1 million in Q4 2024 and $375.5 million in Q3 2024.